INmune Bio adds two directors with rare-disease and business-development backgrounds
The company appointed R. Duane Clark II and James Sapirstein to its board on September 8, 2026, as Ebstrocel nears potential commercialization.
SEC filing
Latest
5 stories
Monday, September 14
Wednesday, September 9
Cocrystal Pharma completes dosing in norovirus challenge study of CDI-988
The company reported no serious adverse events so far, with preliminary efficacy data expected late 2026 or early 2027.
SEC filing
Wednesday, August 19
Cocrystal Pharma posts Phase 1 results for CDI-988, an oral SARS-CoV-2 antiviral candidate
Tuesday, August 18
Cocrystal Pharma adds Carol Brosgart, MD to board of directors
The antiviral biotech named the physician-scientist and veteran biopharma board member to its board effective August 12, 2026.
SEC filing (2)
Monday, August 3
Cocrystal Pharma confirms $5 million OPKO Health private placement in 8-K filing
The filing details the July 31, 2026 stock sale to longtime investor OPKO as Cocrystal's norovirus drug CDI-988 nears Phase 1b topline data.
SEC filing